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Experimental models suggest that increased aldosterone
and sodium intake are associated with renovascular
damage and resultant proteinuria. We hypothesized that
serum aldosterone and urinary sodium would be associated
with urinary albumin excretion, an indicator of kidney
damage. We evaluated 2700 participants (53% women, mean
age 58 years) from the Framingham Offspring Study who
attended a routine examination between 1995 and 1998,
who were free of heart failure and renal failure, and
underwent testing for serum aldosterone, spot urinary
sodium, and urinary albumin excretion (urine albumin/
creatinine ratio, UACR), the latter two indexed to urinary
creatinine. Stepwise multivariable linear regression was used
to evaluate the relations between UACR with urinary sodium
index and serum aldosterone. In multivariable regression,
log urinary sodium index was associated positively with
log-UACR (Po0.0001). UACR levels in the fourth and fifth
quintiles of urinary sodium index were 24% (95% confidence
interval (CI) 3–49%), and twofold higher (95% CI 72–150%),
respectively, relative to the lowest quintile (P-value for
trend across quintiles o0.001). In multivariable models,
log-transformed aldosterone was not related to log-UACR.
The top quintile of serum aldosterone levels was associated
with a 21% higher (95% 1–44%) UACR levels relative to the
lowest quintile. Urinary albumin excretion was strongly
and positively associated in a continuous fashion with
urinary sodium excretion, whereas a weaker nonlinear
positive relation with serum aldosterone was noted.
Our cross-sectional observations raise the possibility that
dietary salt intake may be associated with early renovascular
damage.
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Increased urinary albumin excretion predicts decline in
kidney function.1–4 Albuminuria has been linked to glomer-
ular hyperfiltration that leads to subsequent glomerular
damage.2,5,6 Increased nitrosative stress in renal glomeruli
has been postulated as a precursor of albuminuria7; evidence
for this putative mechanism has been noted in diabetic
kidney disease8–11 and pregnancy-associated renal changes.12
Albuminuria is also a marker of systemic endothelial dys-
function.13–17 Given its predictive clinical utility,1–4 albumi-
nuria has emerged as a sensitive and early biomarker of
both glomerular damage as well as systemic vascular dys-
function.
Substantial experimental evidence has implicated both
increased dietary sodium intake18–21 and higher aldo-
sterone22–26 in the pathogenesis of renovascular injury. In
contrast, human data on the potential role of sodium intake
and aldosterone on renal dysfunction are very limited. In
prior studies, increased urine sodium excretion (a marker of
dietary salt intake) has been associated with albuminuria,
especially in salt-sensitive persons.27–31 Based on the experi-
mental and clinical data noted above, we hypothesized that
increasing serum aldosterone and/or higher salt intake will be
associated with greater albuminuria in unselected individuals
in the community. We used urinary sodium excretion, as
a marker of dietary sodium intake.32–34
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RESULTS
The baseline characteristics of our sample are shown in
Table 1. Figure 1 displays the distribution of urine albumin/
creatinine ratio (UACR) (box plots showing median and
interquartile ranges for unadjusted values) according to
quintiles of serum aldosterone (panel a) and urinary sodium
index (panel b).
Relation between urinary sodium index and albuminuria
In age- and sex-adjusted models, each standard deviation
increment in log urine sodium index was associated with a
22% higher UACR (Po0.001). Multivariable models yielded
similar results (36% higher UACR per standard deviation
increase in log urinary sodium index, P-value o0.0001). In
quintile-based analyses, the fourth quintile of urinary sodium
index was associated with a 24% higher adjusted UACR (95%
confidence interval (CI) 3–49%), whereas the upper quintile
was associated with a doubling of UACR (95% CI 72–150%;
Table 2) relative to the lowest quintile that served as referent.
The association between log urinary sodium index and log
UACR was maintained in secondary analyses excluding parti-
cipants on diuretics (Table 3), participants with prevalent
cardiovascular disease, diabetes, chronic kidney disease, and
hypertension.
Relations between serum aldosterone and microalbuminuria
Log aldosterone was associated with log UACR in age- and
sex-adjusted models (9% higher per standard deviation
increase in log aldosterone, P¼ 0.005), but not in fully
adjusted models (P¼ 0.09). In quintile-based analyses, the
upper quintile of serum aldosterone was associated with 21%
higher UACR (95% CI 1–44%; Table 2) compared to the
referent group. Adjusted UACR in the second, third, and
fourth quintiles of serum aldosterone were not different from
the referent group. When analyses were performed excluding
participants with prevalent cardiovascular disease, hyper-
tension, or chronic kidney disease, these findings were no
longer statistically significant (Table 3).
Effect modification
The associations of urinary sodium index with UACR did not
vary by age or sex (Table 3). For aldosterone, relations were
Table 1 | Baseline characteristics of study sample (n=2700)
Age 58710
Female (%) 53
Systolic blood pressure (mm Hg) 128719
Diastolic blood pressure (mm Hg) 7679
Hypertension (%) 39
Hypertension treatment (%) 26
Diuretic use (%)a 7
Angiotensin-converting enzyme inhibitor use (%) 10
Left ventricular hypertrophy by electrocardiogram
with strain (%)
0.3
Total/HDL cholesterol 4.471.5
Body mass index (kg/m2) 27.975.1
Diabetes (%) 9
Current smoking (%) 15
Serum creatinine (mg/dl) 0.970.2
Prevalent cardiovascular disease (%) 9
Menopausal status (%)
Pre-menopausal 58
Post-menopausal, taking hormone replacement therapy 14
Post-menopausal, not taking hormone replacement
therapy
28
Serum aldosteroneb (ng/dl) 10 (7, 14)
Urinary sodium indexed to urinary creatinineb (mmol/g) 96 (62, 141)
Urinary albumin indexed to urinary creatinineb (mg/g) 6.1 (2.8, 14.2)
Data are mean7standard deviation unless otherwise specified.
aIncludes lasix, thiazides, and potassium-sparing diuretics.
bMedian (25th, 75th percentile).
HDL, high-density lipoprotein.
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Figure 1 | Median and interquartile ranges for albuminuria by
quintiles of aldosterone and urinary sodium indexed to urinary
creatinine. Median (lines) and interquartile ranges (boxes) (a) for
albuminuria by quintiles of aldosterone and (b) urinary sodium
indexed to urinary creatinine. Cut points for quintiles of aldosterone
were 6.0, 8.0, 11.0, and 14.0 ng/dl, and cut points for quintiles of
urinary sodium index were 55, 83, 111, and 155 mmol/g.
Table 2 | Linear regression for quintiles of aldosterone and
urinary sodium indexed to urinary creatinine and UACRa
Multiplicative effect
on UACR (95%
confidence interval)
P-value
for trend
Quintile of UNACRb
First (referent) 1.0
Second 0.95 (0.8–1.14)
Third 1.11 (0.93–1.34)
Fourth 1.24 (1.03–1.49)
Fifth 2.08 (1.72–2.50)
Trend across quintiles 1.19 (1.15–1.25) o0.0001
Quintile of aldosteroneb
First (referent) 1.0
Second 1.07 (0.89–1.28)
Third 1.07 (0.90–1.26)
Fourth 1.06 (0.88–1.29)
Fifth 1.21 (1.01–1.44)
Trend across quintiles 1.05 (1.00–1.09) =0.02
UACR, urinary albumin indexed to urinary creatinine; UNACR, urinary sodium
indexed to urinary creatinine.
aModels adjusted for age, sex, diabetes, diuretic use, systolic blood pressure,
diastolic blood pressure, hypertension treatment, serum creatinine, and smoking. All
models contain both log aldosterone and log urine sodium index.
bCompared between each quintile and the referent category; quintile cut points are
55, 83, 111, and 155 mmol/g for UNACR and 6.0, 8.0, 11.0, and 14.0 ng/dl for
aldosterone.
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weakly significant among younger individuals and women.
Because the top quintile of serum aldosterone may have the
greatest effect on UACR, we examined whether the magni-
tude of this effect differed by quintile of urinary sodium
index. There was no interaction between the top quintile of
serum aldosterone and the top quintile of urinary sodium
index with regard to their effects on UACR (P-value¼ 0.31).
DISCUSSION
Principal findings
We observed that urinary sodium index is strongly and
positively associated with UACR. In our sample, serum
aldosterone was weakly associated with UACR in a nonlinear
fashion; only the top quintile of serum aldosterone was
associated with higher adjusted UACR levels.
Potential mechanisms underlying observed associations
Our data indicating a positive association of urine sodium
index with UACR are consistent with animal studies
indicating that high salt intake has a deleterious effect on
the renal vasculature. Rats given saline to drink demonstrate
vascular and glomerular sclerosis, interstitial fibrosis of the
glomeruli and renal tubules18 and increased albuminuria,35
possibly due to hyperfiltration with resultant increased albu-
min excretion.36 Alterations in charge-dependent selective
permeability of the glomerular basement membrane have
also been described with salt loading and likely contribute to
the development of albuminuria. Experimental models of
nitric oxide blockade demonstrate profound albuminuria,
glomerulosclerosis, and hypertension that is potentiated by
dietary salt excess.21,37 It has been hypothesized that increases
in nitric oxide synthesis may be an adaptive mechanism to
increase urinary sodium excretion in response to increased
dietary intake.38
Prior human studies support these findings as well. In a
referral sample enriched for hypertension, urinary sodium
was associated with urinary albumin excretion in unadjusted
analyses.27 In a large community-based sample enriched for
participants with high urinary albumin excretion, urinary
sodium was positively associated with urinary albumin
excretion.31 We extend these findings now to a community-
based sample not enriched for hypertension or greater
urinary albumin excretion. We also provide a more detailed
analysis illustrating the robustness of this association among
multiple subgroups. Not all prior findings have been
consistent: an analysis of nutrient intake in relation to
urinary albumin excretion in the INTERMAP study failed to
find an association with urinary sodium.39 Differences from
our study may have arisen because in the INTERMAP study
urinary albumin was evaluated as a dichotomous outcome
(o30 and 30–299.9 mg/24 h), whereas we examined UACR as
a continuous variable.
Our cross-sectional data are consistent with a moderately
deleterious effect of aldosterone on albuminuria only in the
setting of relatively higher aldosterone levels (values in the
top quintile). Aldosterone may mediate kidney injury
through renal inflammation, fibrosis, and thrombosis, and
these effects may be potentiated by salt intake.35 Stroke-prone
hypertensive rats fed saline-drinking water that were treated
with spironolactone had significantly lower urine protein
excretion despite similar blood pressures than rats given
placebo.40
Strengths and limitations
Strengths of our study include a large sample size, with well-
characterized covariate information and the assessment of
serum aldosterone, urine sodium index, and UACR blinded
to the results of each other and to other clinical information.
Further, we were able to evaluate confounding by use of
medications, including angiotensin-converting enzyme inhi-
bitors and diuretics, by conducting subgroup analyses.
Important limitations of our investigation include the use
of spot urine specimen for assessment of albuminuria, urine
sodium index, and serum aldosterone. However, UACR on
a spot urine specimen has been shown to approximate 24-h
Table 3 | Linear regression for quintiles of aldosterone
and urinary sodium indexed to creatinine and UACR by
subgroupsa
Quintile rank
on UACR (95%
confidence interval) P-value
Trend across UNACR quintilesb
Participants not on diuretics 1.19 (1.14, 1.25) o0.0001
No diabetes 1.20 (1.15, 1.26) o0.0001
No chronic kidney disease 1.20 (1.15, 1.26) o0.0001
No hypertension 1.19 (1.13, 1.26) o0.0001
No CVD 1.19 (1.14, 1.24) o0.0001
Gender
Men 1.19 (1.11, 1.28) o0.0001
Women 1.19 (1.13, 1.25) o0.0001
Age
p60 years 1.24 (1.17, 1.31) o0.0001
460 years 1.15 (1.08, 1.22) o0.0001
Trend across aldosterone quintilesb
Participants not on diuretics 1.05 (1.00, 1.10) 0.018
No diabetes 1.05 (1.00, 1.09) 0.02
No chronic kidney disease 1.04 (0.99, 1.09) 0.06
No hypertension 1.02 (0.97, 1.08) 0.40
No CVD 1.03 (0.98, 1.08) 0.13
Gender
Men 1.04 (0.97, 1.11) 0.29
Women 1.06 (1.00, 1.12) 0.03
Age
p60 years 1.06 (1.01, 1.13) 0.02
460 years 1.02 (0.96, 1.09) 0.56
CVD, cardiovascular disease; UACR, urinary albumin indexed to urinary creatinine;
UNACR, urinary sodium indexed to urinary creatinine.
aModels adjusted for age, sex, diabetes, diuretic use, systolic blood pressure,
diastolic blood pressure, hypertension treatment, serum creatinine, and smoking. All
models contain both log aldosterone and log urine sodium index.
bComparison between each quintile and the referent category; quintile cut-points
are 55, 83, 111, and 155 mmol/g for UNACR and 6.0, 8.0, 11.0, and 14.0 ng/dl for
aldosterone.
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urine collections,41 and urine sodium, when indexed to
urinary creatinine, has been shown to reasonably reflect 24-h
urine sodium excretion and dietary intake,42,43 although
prospective studies have not confirmed that spot urinary
sodium approximates dietary sodium intake. The use of a
single estimation of serum aldosterone instead of 24-h
urinary aldosterone may have attenuated associations and
limited our ability to detect more modest effects of
aldosterone on UACR. The predominantly Caucasian study
sample limits the generalizability of our findings to other
ethnicities. Levels of UACR in the range of our community-
based study sample have not been shown to be associated
with significant renal injury. Therefore, the generalizability of
these findings to clinically significant chronic kidney disease
progression is uncertain. However, levels of UACR in this
range are clearly related to cardiovascular disease risk.44
Lastly, our study is cross-sectional, and therefore causality
cannot be inferred.
Public health implications
Our findings may have public health relevance, because of
our results suggesting that higher salt intake is associated
with greater UACR. Not only is albuminuria an early
indicator of kidney dysfunction, but it is also associated
with incident cardiovascular disease,44–46 cardiovascular
mortality,47–49 and all-cause mortality.50 Further, the anti-
proteinuric effect of angiotensin-converting enzyme inhibi-
tion was shown to be offset by increases in dietary sodium
from 50 to 200 mmol/day, a quantity that is well within
the range of customary Western dietary intake patterns.51
Our observational data, if confirmed, would support
recommendations for limiting dietary sodium intake, with
the added possible benefit of lowering UACR.
Conclusions
In our large community-based sample, urinary sodium
index was strongly associated with UACR, whereas a weaker
nonlinear positive relation with serum aldosterone was
noted. These observations are consistent with the hypo-
thesis that higher salt intake may be associated with early
renovascular damage. Additional research is warranted to
confirm our findings, and if confirmed further elucidate the
mechanisms underlying the association between aldosterone,
sodium, and albuminuria.
MATERIALS AND METHODS
Study sample
The Framingham Offspring Study began in 1971 with the
enrollment of 5124 men and women who were the children of the
original cohort and the spouses of the children. Offspring study
participants are examined approximately every 4 years.52,53 The
current investigation is comprised of attendees of the sixth Offspring
cohort examination cycle in 1995–1998. Of 3532 attendees,
individuals were excluded for the following indications: 539 were
excluded because of nonavailable urinary sodium indexed to urinary
creatinine information (urinary sodium index), 34 because of
prevalent congestive heart failure, 14 because of serum creatinine
42.0 mg/dl, 35 because of UACR4300 mg/g, and 100 because of
missing serum aldosterone, 27 because of their use of spirono-
lactone, and 83 because of missing covariate information. After
exclusions, 2700 participants (1437 women) remained eligible. The
protocol was approved by the Boston Medical Center Institutional
Review Board and all participants provided written informed
consent.
Measurement of serum aldosterone, urinary sodium, and
urinary microalbumin
Serum aldosterone was measured from fasting blood samples
with participants in the supine position for about 5 min prior to
venipuncture. Most samples were obtained between 0800 and 0900
hours and after an overnight fast. Venous blood was centrifuged and
serum stored at 701C until measurement. Serum aldosterone was
measured using a radioimmunoassay (Quest Diagnostics, CA, USA).
The assay was highly sensitive (detection limit 1 ng/dl) and had an
intra-assay coefficient of variation from 3.8 to 6% and an interassay
coefficient of variation of 4.0–9.8%.
Spot urine samples (3 ml) were collected at the time of
phlebotomy and then maintained at 201C until analysis. Urine
sodium was measured using an automated ion-electrode method.
Samples were analyzed in duplicate with an average intra-assay
coefficient of variation of 0.8%. A modified Jaffe method was used
to measure urinary creatinine concentration (average intra-assay
coefficient of variation of 1.7–3.8%). Urinary sodium excretion is
expressed as mmol of sodium per gm of urinary creatinine (referred
to as urine sodium index).
Urine albumin concentration was measured by immuno-turbi-
metry (Tina-quant Albumin assay; Roche Diagnostics, Indianapolis,
IN, USA). Urinary microalbumin was indexed to urinary creatinine
(as the UACR) in order to account for differences in urine
concentration. The UACR is a validated, reliable single-sample
measure of urinary albumin excretion that is highly correlated with
albumin excretion rates assessed by 24-h urine collection.41,54
Assessment of risk factors
Details regarding the methods of risk factor measurement and
laboratory analysis have been described elsewhere.55 Each examina-
tion included a cardiovascular disease assessment and blood testing.
Participants with fasting glucose level X126 mg/dl (7.0 mmol/l)
and/or receiving oral hypoglycemic or insulin treatment for diabetes
were defined as diabetic. Individuals with a systolic blood pressure
X140 mm Hg or diastolic blood pressure X90 mm Hg (average
of two readings taken by the examining Heart Study physician)
or receiving medication for treatment of hypertension were
categorized as hypertensive. No participants were using angio-
tensin-receptor blockers at the sixth examination cycle. Fasting
lipid measures included serum total and high-density lipoprotein
cholesterol. Serum creatinine was measured using the modified
Jaffe method. Smoking status was defined as smoking one or more
cigarettes/day in the year preceding the examination. Body mass
index was defined as weight (kilograms) divided by the square of
height (meters).
Statistical analysis
The distributions of serum aldosterone, urine sodium index, and
UACR were positively skewed, so we used natural logarithmic
transformation to normalize their distributions. We used multiple
linear regression56 (implemented in SAS57) to examine the relations
of UACR (dependent variable) with serum aldosterone and urine
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sodium index (independent variables). Serum aldosterone and
urine sodium index were modeled as continuous variables (log-
transformed) and as categorical variables (quintiles for pooled sexes,
distributions being similar in the two sexes). Two types of
multivariable models were constructed to evaluate the relations of
quintiles of aldosterone and urine sodium index to UACR in order
to determine whether a threshold effect exists:
a. multicategory models, comparing the adjusted least-squares
means for UACR in each of the second to fifth quintile with
values for the first quintile of aldosterone or urine sodium index
serving as referent.
b. Trend models, assessing if there was a linear trend for increasing
UACR across the quintiles of serum aldosterone or urine
sodium index.
All multivariable models adjusted for age and sex. In order to create
a parsimonious model, we implemented stepwise forward selection
(Po0.05 for entry and retention in models), using the following
eligible variables: left ventricular hypertrophy with strain by
electrocardiogram, diuretic use (including lasix, thiazides, and
potassium-sparing diuretics), hypertension, angiotensin-converting
enzyme inhibitor use, total/high-density lipoprotein cholesterol,
smoking, body mass index, menopausal status (premenopausal,
postmenopausal on hormone replacement therapy, postmenopausal
not on hormone replacement therapy), serum creatinine, prevalent
cardiovascular disease, and diabetes. Serum aldosterone and urine
sodium index were included in all models; therefore, aldosterone
was adjusted for urine sodium index and urine sodium index
was adjusted for serum aldosterone. We have previously shown that
urinary sodium is a strong correlate of serum aldosterone.58 The
following variables, in addition to age and sex, entered the stepwise
models and were then included in the final linear regression models:
diabetes, diuretic use, systolic blood pressure, diastolic blood
pressure, hypertension treatment, serum creatinine, and smoking.
Additional analyses
We evaluated for effect modification by age and sex by incorporating
appropriate interaction terms in models with log serum aldosterone
and log urine sodium index. We also assessed for an interaction
between the top quintile of urine sodium index and serum
aldosterone on UACR. The following secondary analyses were
performed: (a) excluding participants on diuretics; (b) excluding
participants with diabetes; (c) excluding participants with chronic
kidney disease, defined as glomerular filtration rate o60 ml/min/
1.73 m2; (d) excluding participants with hypertension; (e) excluding
participants with prevalent cardiovascular disease. A two-sided
P-valueo0.05 was considered statistically significant.
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